Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A)
- Target
- PDE7A
- Molecular classification
- Enzyme, 3',5'-cyclic nucleotide phosphodiesterase
01
Overview
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A) is an enzyme encoded by the PDE7A gene in humans. It specifically hydrolyzes cAMP—a second messenger involved in diverse signaling pathways, including immune modulation, muscle function, and neuronal signaling[3][8]. PDE7A, along with its closely related isoform PDE7B, belongs to the PDE7 family and shows minimal activity toward cGMP[3]. PDE7A is expressed in various tissues and is being explored as a therapeutic target for neurological, immune, and substance use disorders. Although no PDE7A-targeting drugs are currently approved, selective inhibition of this enzyme is viewed as a promising strategy for modulating cAMP levels with potentially fewer side effects compared to related phosphodiesterases[2][4][6].
- Other names
- Phosphodiesterase 7AcAMP-specific phosphodiesterase 7AHigh affinity 3',5'-cyclic-AMP phosphodiesterase 7A
02
Mechanism of action
Inhibition of cAMP hydrolysis leading to increased intracellular cAMP Indirect modulation of cAMP–PKA pathway signaling (affecting CREB/ERK downstream signaling)
03
Biological functions
Hydrolysis of cyclic adenosine monophosphate (cAMP)Regulation of intracellular cAMP levelsSignal transductionModulation of T cell function (e.g. cytokine production, proliferation)May play roles in muscle signal transduction
04
Disease associations
Neurological disease (as a potential target for therapy)Respiratory diseaseAlcohol use disorder (AUD), with sex-specific effects in animal modelsImmune disorders (role in T cell function and possible therapeutic modulation)Other: Possible involvement in cancers and endocrine-related diseases (pituitary, thyroid, testes, though specifics are under investigation)
05
Safety considerations
Off-target effects are likely less frequent than with PDE4 inhibitors (notably fewer gastrointestinal side effects)Long-term effects in humans are not yet established, as no approved PDE7A-targeted drugs are on the market
06
Interacting drugs
BRL50481 (selective PDE7A inhibitor used in research)
1 more in the full profile.
07
Biomarkers
Changes in cAMP levels or downstream effectors (such as pCREB, BDNF) may serve as biomarkers of pharmacodynamic response in preclinical studies
Beyond the preview
Go deeper on High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (PDE7A).